Recombinant Hepatitis B vaccine
ApprovedVaccine
NovartisRecombinant Hepatitis B vaccine is one of 76 biologic programs targeting Hepatitis. It is currently in Approved.
3
Indications
9
Total Trials
1
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Recombinant Hepatitis B vaccine
NovartisApproved
Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatitis B7 trials
Show 4 more trials
Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine
Unknown status·JJiangsu Province Centers for Disease Control and Prevention·Phase 4·NCT06209398·510 enrolled
Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts
Completed·—·Phase 4·NCT02732054·16 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]